Williams v. Daiichi Sankyo, Inc.

13 F. Supp. 3d 426, 2014 WL 1391240
CourtDistrict Court, D. New Jersey
DecidedApril 9, 2014
DocketCivil Action Nos. 14-863 (JEI/AMD), 14-864 (JEI/AMD)
StatusPublished
Cited by3 cases

This text of 13 F. Supp. 3d 426 (Williams v. Daiichi Sankyo, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Williams v. Daiichi Sankyo, Inc., 13 F. Supp. 3d 426, 2014 WL 1391240 (D.N.J. 2014).

Opinion

OPINION

IRENAS, Senior District Judge:

These two lawsuits, having been removed from the Superior Court of New Jersey by Defendants Forest Laboratories, Inc. and Forest Pharmaceuticals, Inc., come before the Court on Plaintiffs’ Motions to Remand. Because the motions raise the same question of law and have highly similar factual circumstances, the Court considers them together for purposes of efficiency. In support of their motions, Plaintiffs argue that removal of this case was improper because the Defendants violated the “forum defendant rule,” codified at 28 U.S.C. § 1441(b)(2). For the reasons set forth below, Plaintiffs’ motions will be granted, and these two cases will be remanded back to the New Jersey Superior Court.

I.

The facts and procedural history of these two cases are fairly straightforward, and the Court reviews only the necessary facts for deciding the pending motions to remand.

A.

On February 6, 2014, Plaintiffs George and Martha Williams (the ‘Williams Plaintiffs”) filed a Complaint in the Superior Court of New Jersey, Law Division, Atlantic County. Their suit seeks damages for personal injuries and loss of consortium as a result of George Williams’s alleged use of the blood pressure drug olmesaran medox-omil.

The Williams Plaintiffs name six Defendants in their Complaint: Daiiehi Sankyo, Inc.; Daiiehi Sankyo U.S. Holdings, Inc.; Daiiehi Sankyo Co., Ltd.; Forest Laboratories, Inc. (“FLI”); Forest Pharmaceuticals, Inc. (“FPI”); and Forest Research Institute, Inc.1 Their Complaint seeks to [428]*428recover for nineteen causes of action, all pursuant to New Jersey state law.

Five days later, on February 11, the Superior Court issued a Track Assignment Notice (“TAN”) to the Williams Plaintiffs. (Kessler Decl. ¶ 6 (Williams); see also Pis.’ Ex. B (Williams)) In accordance with New Jersey Civil Practice Rule 4:4-1, the Williams Plaintiffs issued summonses for all six Defendants within fifteen days of receiving the TAN, and on February 20th, the Williams Plaintiffs served all of the Defendants except the Japanese Defendant, Daiichi Sankyo Co., Ltd. (Kessler Decl. ¶¶ 7-8 (Williams))2

Also on February 11, before the Williams Plaintiffs served any Defendant, FLI and FPI removed the case to this Court. The Notice of Removal contended that this Court had original jurisdiction over the Williams Plaintiffs’ Complaint pursuant to 28 U.S.C. § 1332’s diversity jurisdiction. (Notice of Removal ¶ 4 (Williams)) There is no dispute that the Williams Plaintiffs are both citizens of Texas. (Compl. ¶¶ 1-2 (Williams)) In addition, the parties do not dispute that Daii-chi Sankyo, Inc. is a citizen of Delaware and New Jersey; Daiichi Sankyo U.S. Holdings, Inc. is a citizen of Delaware and New Jersey; Daiichi Sankyo Co., Ltd. is a citizen of Japan; FLI is a citizen of Delaware and New York; FPI is a citizen of Delaware and Missouri; and Forest Research Institute, Inc. is a citizen of New Jersey. (Notice of Removal ¶¶ 7-12 (Williams)) Finally, neither party disputes that the amount in controversy exceeds $75,000. (Id. ¶ 15)

Between FLI and FPI’s Notice of Removal on February 11 and service on February 20, Defendant Forest Research Institute, Inc. filed an Answer in this Court on February 17. On March 13, the Williams Plaintiffs filed the pending motion to remand back to the Superior Court, Atlantic County. Defendants FLI and FPI oppose this motion. During the course of briefing the motion to remand, FLI and FPI filed an Answer on March 21, and Daiichi Sankyo U.S. Holdings, Inc. and Daiichi Sankyo, Inc. filed a separate Answer on the same day.

B.

Plaintiffs Shelly and Abu Rahman (the “Rahman Plaintiffs”) also filed suit in the New Jersey Superior Court, Law Division, Atlantic County, on February 6, 2014. Just like the Williams Plaintiffs, the Rah-man Plaintiffs bring their suit to recover for personal injuries and loss of consortium, allegedly resulting from Shelly Rah-man’s use of the blood pressure drug ol-mesaran medoxomil.

Also like the Williams Plaintiffs, the Rahman Plaintiffs name the same nineteen state-law claims and the same six Defendants in their suit.3 Defendants FLI and FPI removed the Rahmans’ suit to this Court on February 11. In their Notice of Removal, FLI and FPI again contended that this Court’s diversity jurisdiction, pursuant to 28 U.S.C. § 1332, permitted removal. (Notice of Removal ¶ 4 (Rahman)) Neither party disputes that the Rahman Plaintiffs are citizens of Pennsylvania, while the Defendants’ citizenship is the same as listed supra. (Id. ¶¶ 6-12) Again, [429]*429neither party disputes that the amount in controversy exceeds $75,000. (Id. ¶ 15)

On the same date as FLI and FPI’s removal, February 11, the Superior Court issued a TAN to the Rahman Plaintiffs. (Kessler Decl. ¶ 6 (Rahman)) On February 12, the Rahman Plaintiffs issued summonses for each Defendant, which they served with a copy of the Complaint and TAN to all Defendants except the Japanese citizen, Daiichi Sankyo Co., Ltd. on February 14. (Id. ¶¶7-8) On February 17, Forest Research Institute, Inc. filed an Answer.

On March 13, the Rahman Plaintiffs filed the pending motion to remand this case back to the Superior Court, Atlantic County. FLI and FPI oppose this motion. During the course of briefing the motion, FLI and FPI filed an Answer on March 21, and Daiichi Sankyo U.S. Holdings, Inc. and Daiichi Sankyo, Inc. filed an Answer on the same day.

The pending motions to remand are now fully briefed and ripe for consideration.

II.

Defendants FLI and FPI removed these two cases pursuant to the federal removal statute, 28 U.S.C. § 1441, citing this Court’s diversity jurisdiction under § 1332. As detailed supra, the parties do not dispute that complete diversity exists among the Plaintiffs and Defendants, and the amount in controversy in both cases exceeds $75,000. However, the Williams and Rahman Plaintiffs contend, among other arguments, that FLI and FPI’s removal failed to comply with the requirements of § 1441.

Under 28 U.S.C. § 1441(a), a defendant may remove a case from a state court to federal district court if the federal courts have original jurisdiction over the ease. Where the federal court’s original jurisdiction is based on diversity, § 1441(b) imposes an additional condition known as the “forum defendant rule.” The relevant statute provides:

A civil action otherwise removable solely on the basis of the jurisdiction under section § 1332(a) of this title may not be removed if any of the parties in interest properly joined and served as defendants is a citizen of the State in which such an action is brought.

§ 1441(b)(2). The federal removal statute is “to be strictly construed against removal.” Samuel-Bassett v. KIA Motors Am., Inc.,

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
13 F. Supp. 3d 426, 2014 WL 1391240, Counsel Stack Legal Research, https://law.counselstack.com/opinion/williams-v-daiichi-sankyo-inc-njd-2014.